-
90Life context of pharmacological academic performance enhancement among university students – a qualitative approachBMC Medical Ethics 15 (1): 23. 2014.Academic performance enhancement or cognitive enhancement (CE) via stimulant drug use has received increasing attention. The question remains, however, whether CE solely represents the use of drugs for achieving better academic or workplace results or whether CE also serves various other purposes. The aim of this study was to put the phenomenon of pharmacological academic performance enhancement via prescription and illicit (psycho-) stimulant use (Amphetamines, Methylphenidate) among university…Read more
-
14"The Protestant Ethic versus the" New EthicIn Hartmut Lehmann & Guenther Roth (eds.), Weber's Protestant ethic: origins, evidence, contexts, Cambridge University Press. 1993.
-
1Perspektive-Symbol, Konvention, WirklichkeitZeitschrift für Ästhetik Und Allgemeine Kunstwissenschaft 31 (2): 214-230. 1986.
-
62Intellectual Property and Access to Essential Medicines: A Tenuous Link?Asian Bioethics Review 5 (4): 376-382. 2013.
-
151Access to Healthcare and the Pharmaceutical SectorCambridge Quarterly of Healthcare Ethics 20 (2): 309-325. 2011.Health is higher on the international agenda than ever before, and improving the health of poor people is a central issue in development. Poor people suffer from far higher levels of ill health, mortality, and malnutrition than do those better off, and their inadequate health is one of the factors keeping them poor or for their being poor in the first place. Health is a crucially important economic asset, particularly for poor people. Their livelihoods depend on it. When poor people become ill o…Read more
-
58Corporate Philanthropy: The “Top of the Pyramid”Business and Society Review 112 (3): 315-342. 2007.
-
79Most like it but some don't – attitudes of vocational trainees in general practice towards evidence‐based medicineJournal of Evaluation in Clinical Practice 17 (4): 615-620. 2011.
-
101Vergemeinschaftung and Vergesellschaftung in Max Weber: A reconstruction of his linguistic usageHistory of European Ideas 37 (4): 454-465. 2011.When Max Weber made use of the terms ?Vergemeinschaftung? and ?Vergesellschaftung? in the first chapter of ?Economy and Society?, he was among other things alluding to Ferdinand Tönnies' well- known usage of ?Gemeinschaft? and ?Gesellschaft?, as well as to related conceptions in the work of Georg Simmel. However, Weber's usage not only differed from the senses in which Tönnies and Simmel used these terms; he had himself altered his own usage since the early draft of this chapter, published in 19…Read more
-
Holzwege für den aufrechten Gang: Christliche Werte als Handlungsorientierung für unternehmerische EntscheidungenFreiburger Zeitschrift für Philosophie Und Theologie 52 (3). 2005.
-
19Kant und der Katholizismus: Ausstellungskatalog (edited book)Harrassowitz. 2005.Jahrhunderts entspannt. So wurde Kant als Metaphysiker neu entdeckt. Ausstellung und Katalog dokumentieren diese wechselhafte Geschichte der katholischen Rezeption Kants in den vergangenen 200 Jahren.
-
36Die Modernisierung des psychischen Apparats: seelische Strukturen im kulturellen Wandel (edited book)Brandes & Apsel. 2009.
-
29Der Gegensatz Marx' zu Hegel. Mit besonderer Berücksichtigung von 'Nationalökonomie und Philosophie'Zeitschrift für Philosophische Forschung 25 (1). 1971.
-
41"Werden" und "Proletariat". Zum Verlust des Konkreten bei Hegel und MarxZeitschrift für Philosophische Forschung 29 (1). 1975.
-
189The Corporate Social Responsibility of The Pharmaceutical IndustryBusiness Ethics Quarterly 15 (4): 577-594. 2005.In recent years society has come to expect more from the “socially-responsible” company and the global HIV/AIDS pandemic in particular has resulted in some critics saying that the “Big Pharma” companies have not been living up to their social responsibilities. Corporate social responsibility can be understood as the socio-economic product of the organizational division of labor in complex modern society. Global poverty and poor health conditions are in the main the responsibilities of the world’…Read more
-
97Bad Medicine. The Prescription Drug Industry in the Third World. M. Silverman, M. Lydecker, Ph. R. Lee. Stanford, California: Stanford University Press, 1992, ISBN 0-8047-1669- (review)Cambridge Quarterly of Healthcare Ethics 2 (3): 388. 1993.
-
97Bioethics Here and in Poor Countries: A CommentCambridge Quarterly of Healthcare Ethics 2 (1): 5. 1993.There has been a tremendous increase in interest in bioethics, which has come in direct response to the substantial advances in biomedical research and medical technology over the past 30 years. The more sophisticated medical science and technology becomes, the more sophisticated are questions that are raised: Who has the right to decide whether a medical treatment should be initiated, continued, or stopped? How much information are healthcare professionals required to give to patients? When sho…Read more
-
200Professional Organizations and Healthcare Industry Support: Ethical Conflict?Cambridge Quarterly of Healthcare Ethics 3 (2): 236. 1994.A good deal of attention has been recently focused on the presumed advertising excesses of the healthcare industry in its promotion techniques to healthcare professionals, whether through offering gratuities such as gifts, honoraria, or travel support2-6 or through deception. Two basic concerns have been expressed: Does the acceptance of gratuities bias the recipient, tainting his or her responsibilities as the patient's agent? Does acceptance of the gratuity by the healthcare professional contr…Read more
-
Corporate philanthropy as an integrated concept : the case of the Novartis Foundation for sustainable developmentIn Ananda Das Gupta (ed.), Ethics, business and society: managing responsibly, Response Books. 2010.
-
126Corporate Responsibilities for Access to MedicinesJournal of Business Ethics 85 (S1). 2009.Today there is a growing wave of demands being placed upon the pharmaceutical industry to contribute to improved access to medicines for poor patients in the developing countries. 1 This article aims to contribute to the development of a systematic approach and broad consensus about shared benchmarks for good corporate practices in this area. A consensus corridor on what constitutes an appropriate portfolio of corporate responsibilities for access to medicines -especially under conditions of 'fa…Read more